

Supplementary Information

Article Title: Managing cardiovascular and cancer risk associated with JAK inhibitors

Journal Name: Drug Safety

Author Names: Victor Yang, Tue W Kragstrup, Christopher McMaster, Pankti Reid, Namrata Singh, Stine R Haysen, Philip C Robinson, David FL Liew

Corresponding Author: David FL Liew

Affiliations: Department of Rheumatology, Austin Health, Melbourne, Victoria, Australia; Department of Clinical Pharmacology and Therapeutics, Austin Health, Melbourne, Victoria, Australia; Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia

Email: david.liew@austin.org.au

Online Resource 1: Literature search strategy

Line	Search string
1	JAK inhibitor or Janus kinase inhibitor or Jakinib
2	tofacitinib or Xeljanz or Jaquinus or Tofacinix or CP-690550
3	baricitinib or Olumiant or INCB28050 or LY3009104
4	upadacitinib or Rinvoq or ABT-494
5	filgotinib or Jyseleca or GLPG0634 or GS-6034
6	1 or 2 or 3 or 4 or 5
7	major adverse cardiovascular events or MACE or sudden cardiac death or myocardial infarction or cardiac event or cardiovascular safety or cardiovascular risk
8	cancer or malignancy or lymphoma or neoplasm
9	venous thromboembolism or vte or pulmonary embol* or deep vein thrombosis
10	infection or herpes zoster or shingles
11	6 and (7 or 8 or 9 or 10)